CD274 and Fever: Other commonly reported TEAEs were pyrexia (22.2%) in the cHL anti‐PD‐1/PD‐L1 naïve cohort; nausea (33.3%), pyrexia (25.0%), diarrhea (25.0%), and pruritus (25.0%) in the cHL anti‐PD‐1/PD‐L1 progressors cohort; and abdominal pain (29.4%), peripheral edema (29.4%), decreased appetite (23.5%), diarrhea (23.5%), fatigue (23.5%), and nausea (23.5%) in the DLBCL cohort.